| When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH JH Levy, W Ageno, NC Chan, M Crowther, P Verhamme, JI Weitz Journal of Thrombosis and Haemostasis 14 (3), 623-627, 2016 | 389 | 2016 |
| COVID-19 coagulopathy, thrombosis, and bleeding NC Chan, JI Weitz Blood, The Journal of the American Society of Hematology 136 (4), 381-383, 2020 | 142 | 2020 |
| Prevention of venous thromboembolism in 2020 and beyond M Nicholson, N Chan, V Bhagirath, J Ginsberg Journal of clinical medicine 9 (8), 2467, 2020 | 139 | 2020 |
| Direct oral anticoagulants: evidence and unresolved issues N Chan, M Sobieraj-Teague, JW Eikelboom The Lancet 396 (10264), 1767-1776, 2020 | 119 | 2020 |
| Laboratory measurement of the direct oral anticoagulants BJ Dale, NC Chan, JW Eikelboom British journal of haematology 172 (3), 315-336, 2016 | 117 | 2016 |
| Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants NC Chan, JW Eikelboom, JI Weitz Circulation research 118 (9), 1409-1424, 2016 | 116 | 2016 |
| New developments in anticoagulants: past, present and future JI Weitz, J Harenberg Thrombosis and haemostasis 117 (07), 1283-1288, 2017 | 109 | 2017 |
| Dabigatran is less effective than warfarin at attenuating mechanical heart valve‐induced thrombin generation IH Jaffer, AR Stafford, JC Fredenburgh, RP Whitlock, NC Chan, JI Weitz Journal of the American Heart Association 4 (8), e002322, 2015 | 102 | 2015 |
| Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism NC Chan, V Bhagirath, JW Eikelboom Vascular Health and Risk Management, 343-351, 2015 | 99 | 2015 |
| Antithrombotic agents: new directions in antithrombotic therapy NC Chan, JI Weitz Circulation research 124 (3), 426-436, 2019 | 97 | 2019 |
| Real‐world variability in dabigatran levels in patients with atrial fibrillation NC Chan, M Coppens, J Hirsh, JS Ginsberg, JI Weitz, T Vanassche, ... Journal of Thrombosis and Haemostasis 13 (3), 353-359, 2015 | 78 | 2015 |
| Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study S Piran, H Traquair, N Chan, V Bhagirath, S Schulman Research and practice in thrombosis and haemostasis 2 (4), 684-688, 2018 | 74 | 2018 |
| Peripheral oxygen saturation in older persons wearing nonmedical face masks in community settings NC Chan, K Li, J Hirsh JAMA 324 (22), 2323-2324, 2020 | 71 | 2020 |
| New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and … NC Chan, JS Paikin, J Hirsh, MN Lauw, JW Eikelboom, JS Ginsberg Thrombosis and haemostasis 112 (05), 798-807, 2014 | 68 | 2014 |
| Novel antithrombotic strategies for treatment of venous thromboembolism JI Weitz, NC Chan Blood, The Journal of the American Society of Hematology 135 (5), 351-359, 2020 | 66 | 2020 |
| Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure JD Douketis, G Wang, N Chan, JW Eikelboom, S Syed, R Barty, KA Moffat, ... Journal of Thrombosis and Haemostasis 14 (1), 89-97, 2016 | 53 | 2016 |
| Advances in antithrombotic therapy JI Weitz, NC Chan Arteriosclerosis, thrombosis, and vascular biology 39 (1), 7-12, 2019 | 48 | 2019 |
| Betrixaban (PRT054021): pharmacology, dose selection and clinical studies NC Chan, J Hirsh, JS Ginsberg, JW Eikelboom Future Cardiology 10 (1), 43-52, 2014 | 48 | 2014 |
| A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal NC Chan, D Siegal, MN Lauw, JS Ginsberg, JW Eikelboom, GH Guyatt, ... Journal of thrombosis and thrombolysis 40, 231-239, 2015 | 43 | 2015 |
| Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? N Chan, PT Sager, J Lawrence, P Reilly, S Berkowitz, D Kubitza, ... American heart journal 199, 59-67, 2018 | 42 | 2018 |
